Other
Laryngomalacia
3
Pipeline Programs↗
0
Active Trials↗
2
Companies Involved↗
Laryngomalacia is an early-stage landscape with 3 programs across 2 companies. The most active players are Dexcel Pharma Technologies Ltd., Kenvue Brands.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical1
Phase 21
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
3
clinical trials
Withdrawn2 · 67%
Terminated1 · 33%
Clinical Trials
Trial Activity
Laryngomalacia Study
Withdrawn·—·Phase 1·NCT01782560
Initiation of Acid Suppression Therapy Prospective Outcomes for Laryngomalacia
Terminated·—·Phase 1/2·NCT04614974·65 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)